<DOC>
	<DOCNO>NCT02057107</DOCNO>
	<brief_summary>Compare overall survival patient addition docetaxel overall survival patient treat SBRT cetuximab alone . In addition , determine difference progression free survival ( PFS ) , rate local recurrence ( LR ) distant metastasis ( DM ) across SBRT cetuximab + docetaxel arm arm receiving SBRT cetuximab alone . To good resolve impact experimental treatment PFS , LR , DM , patient stratify presence/absence prior cetuximab treatment randomize either control arm ( cetuximab SBRT ) experimental arm ( cetuximab , SBRT , docetaxel ) .</brief_summary>
	<brief_title>Stereotactic Body Radiation Therapy ( SBRT ) With Cetuximab +/- Docetaxel Followed Adjuvant Cetuximab +/- Docetaxel Recurrent , Previously-Irradiated Squamous Cell Carcinoma Head Neck ( SCCHN )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologicallyproven recurrent squamous cell carcinoma head neck ( SCCHN ) , receive prior radiotherapy without chemotherapy . New primary allow location previously irradiate field . Biopsy recommend recurrence mandate per study . This discretion principal investigator . Prior radiation dose least 50 Gy . Disease confine locoregional site encompass stereotactic body radiosurgery `` portal '' Tumor must deem inoperable unresectable either clinical radiographic criterion . These criterion include encasement great vessel , vertebral invasion undue perioperative risk . Prior surgery recurrent new SCCHN allow previously irradiate patient . A minimum 4 week elapse surgery treatment study . However , highrisk pathologic feature present , positive margin , positive lymphadenopathy , perineural angiolymphatic invasion . Karnofsky performance status &gt; 60 ( ECOG 01 ) Prior treatment EGFR Inhibitor allow part prior curative therapy complete least 30 day prior commencement study therapy Any number prior chemotherapy regimen allow Measurable disease image study ( MRI , CT , PETCT physical exam ) Age &gt; 18 Estimated life expectancy &gt; 12 week No prior radiation therapy chemotherapy within 1 month study enrollment ANC &gt; 1000 , PLT &gt; 75,000 , Serum creatinine &lt; 2.5 mg/dL , Bilirubin &lt; 1.5 x upper limit normal ( ULN ) Diabetes must control prior PETCT scanning ( blood glucose &lt; 200 mg/dL ) Ability provide write informed consent Evidence distant metastasis upright chest xray ( CXR ) , compute tomography ( CT ) stag study Patients reproductive age group use effective method birth control . Patients breastfeed , positive pregnancy test exclude study Any comorbidity condition sufficient severity limit full compliance protocol per assessment investigator Concurrent serious infection History know hypersensitivity cetuximab , docetaxel similar agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>